|
1. Biologie
|
|
|
|
3.1 Prévention - Tabac
|
|
|
|
4.10 Dép., diag. & prono. - FDA, EMA, NICE,...
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
5.12.1 Immunothérapies - partenariats
|
|
|
|
|
|
|
5.12.2 Immunothérapies - CAR-T
|
|
|
|
|
|
FDA Approves Another Amazing And Costly Cancer-Killing Gene Therapy [Forbes]
|
|
|
|
|
|
Chang
says Kite (now Gilead) is developing CAR-T treatments for other
cancers. It will test a CAR-T against a target called BCMA in multiple
myeloma, another targeted against cancers caused by the human papilloma
virus, and a third against MAGE3, hoping to to move the technology
beyond cancers of the blood.
|
|
|
|
|
|
|
|
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
|
5.13 WCLC
|
|
|
|
|
5.2 Pharma
|
|
|
Ignyta NSCLC durability data set stage for Pfizer fight [FierceBiotech]
|
|
|
|
|
|
The
limitations of cross-trial comparisons make it impossible to say
exactly how Ignyta’s entrectinib matches up to Pfizer’s Xalkori, the
current go-to drug for ROS1-positive NSCLC patients. But, in the context
of the 32-patient, single-arm study in which it is being tested,
entrectinib is doing a decent job of painting itself as a viable
contender for the crown.
|
|
|
|
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
|
Drug Development Costs Revisited [In the Pipeline]
|
|
|
|
|
|
One
of the things you come away with from studying this issue is that the
cost-per-drug has truly been increasing, and that the (relatively
steady) productivity of the drug industry as a whole is due to lots more
cash being frantically bulldozed into the the furnaces behind the
scenes.
|
|
|
|
|
|
|
5.6 ESMO
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.12 Ethique
|
|
|